# US 2012/0252758 A1 · Novel Bicyclic Pyridinones

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252758 A1
- Document ID: US20120252758A1
- Status: Published application
- Kind: A1
- Application number: 13/433,452
- Filed: 2012-03-29
- Published: 2012-10-04
- Earliest claimed: 2011-03-31
- Assignees: Pfizer Inc.
- Inventors: Martin Youngjin Pettersson; Douglas Scott Johnson; Chakrapani Subramanyam; Christopher John O'Donnell; Christopher William Am Ende; Benjamin Adam Fish; Michael Eric Green; Patrick Bradley Mullins; Cory Michael Stiff; Tuan Phong Tran; Thayalan Navaratnam
- Web page: https://patentgrep.com/patent/US20120252758A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/695: Silicon compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 491/048: the oxygen-containing ring being five-membered
- C07F 7/0812: {comprising a heterocyclic ring}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

## Claims

### Claim 1

A compound having the structure of Formula I:
wherein:
X is a 5- to 14-membered heteroaryl containing 1-3 heteroatoms;
R1 is hydrogen, halogen, C1-6alkyl, C3-6cycloalkyl, C2-6alkenyl or C2-6alkynyl; wherein said alkyl, cycloalkyl, alkenyl or alkynyl may be optionally and independently substituted with one to three of fluoro, cyano, —CF3, hydroxyl, or C1-6alkoxy groups;
R2a and R2b for each occurrence are each independently hydrogen, fluoro, cyano, —CF3, C1-6alkyl, C3-6cycloalkyl, (C4-10)bicycloalkyl, C2-6alkenyl, C2-6alkylidene, or C2-6alkynyl; wherein said alkyl, cycloalkyl, bicycloalkyl, alkenyl, alkylidene or alkynyl may be optionally and independently substituted with cyano, C1-3alkyl or one to three fluoro; or R2a and R2b together with the carbon to which they are bonded form a 3- to 5-membered cycloalkyl optionally substituted with one to three R8;
R3 is —(C(R11)2)t—(C6-10aryl) or —(C(R11)2)t-(5- to 14-membered heteroaryl); wherein said aryl or heteroaryl moieties may be optionally independently substituted with one to five R10;
R4a and R4b are each independently hydrogen, —CF3, or C1-6alkyl, wherein said alkyl is optionally substituted with one to three —CF3, cyano or fluoro; or R4a and R4b together with the carbon to which they are bonded form a 3- to 5-membered cycloalkyl, wherein said cycloalkyl is optionally substituted with one to three of —CF3, cyano, fluoro or C1-6alkyl;
R5a and R5b for each occurrence are each independently hydrogen, —CF3, or C1-6alkyl, wherein said alkyl is optionally substituted with one to three —CF3, cyano or fluoro; or R5a and R5b together with the carbon to which they are bonded form a 3- to 5-membered cycloalkyl, wherein said cycloalkyl is optionally substituted with one to three —CF3, cyano, fluoro or C1-6alkyl;
R6, R7 and R8 are independently hydrogen, —CF3, cyano, halogen, C1-6alkyl or —OR9; provided that R6 and R7 cannot both be —OH;
R9 is hydrogen, C1-6alkyl, C3-6cycloalkyl, C3-6alkenyl or C3-6alkynyl; wherein said alkyl, cycloalkyl, alkenyl or alkynyl may be optionally and independently substituted with cyano, or one to three fluoro;
each R10 is independently hydrogen, halogen, cyano, —CF3, C1-6alkyl, —(C(R11)2)m—(C3-6cycloalkyl), —(C(R11)2)m—((C4-10)bicycloalkyl), —(C(R11)2)m-(4- to 10-membered heterocycloalkyl), —(C(R11)2)m—(C6-10aryl), —(C(R11)2)m-(5- to 10-membered heteroaryl), —(C(R11)2)m—OR12, —C(O)R13, —SF5 or —Si(CH3)3; wherein said alkyl, cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl or heteroaryl moieties may be optionally and independently substituted with one to three R14;
each R11 is independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-4cycloalkyl, fluoro, —CF3, —CHF2 or —OR12; wherein said alkyl, alkenyl, alkynyl or cycloalkyl moieties may be optionally independently substituted with one to three fluoro or cyano;
each R12 is independently hydrogen, C1-6alkyl, —CF3, —(C(R14)2)n—(C3-6cycloalkyl), —(C(R14)2)n-(4- to 10-membered heterocycloalkyl), —(C(R14)2)n—(C6-10aryl) or —(C(R14)2)n-(5- to 10-membered heteroaryl); wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl moieties may be optionally independently substituted with one to three R16;
each R13 is independently C1-6alkyl, —(C(R16)2)p—(C3-6cycloalkyl), —(C(R16)2)p-(4- to 10-membered heterocycloalkyl), —(C(R16)2)p—(C6-10aryl) or —(C(R16)2)p-(5- to 10-membered heteroaryl); wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl moieties may be optionally independently substituted with one to three R16;
each R14 is independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, halogen, cyano, —CF3, —OR9 or —OCF3;
R16 is independently hydrogen, —CF3, cyano, halogen, C1-6alkyl or —OR9; wherein said alkyl moiety may be optionally substituted with one to three R17;
R17 is independently hydrogen, hydroxyl, —CF3, cyano, fluoro, C2-6alkenyl or C2-6alkynyl; wherein said alkenyl or alkynyl moiety may be optionally substituted with one to three hydrogen, fluoro or C1-6alkyl; and
each t, m, n or p is an integer independently selected from 0, 1, 2, 3 and 4;
z is an integer selected from 1 and 2;
y is an integer selected from 1, 2, 3 and 4
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein X is imidazolyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, oxazolyl or pyridyl.

### Claim 3 (depends on 2)

The compound according to claim 2 wherein X is imidazolyl.

### Claim 4 (depends on 3)

The compound according to claim 3 wherein R1 is C1-6alkyl.

### Claim 5 (depends on 4)

The compound according to claim 4 wherein R1 is methyl optionally substituted with one hydroxyl or C1-6alkoxy or one to three fluoro; y is two or three and z is 1.

### Claim 6 (depends on 5)

The compound according to claim 5 wherein R10 is independently hydrogen, halogen, cyano, —CF3, C1-6alkyl, (C4-10)bicycloalkyl, —(C(R11)2)m—(C3-6cycloalkyl), —(C(R11)2)m-(4- to 10-membered heterocycloalkyl), —(C(R11)2)m—(C6-10aryl), —(C(R11)2)m-(5- to 10-membered heteroaryl), —(C(R11)2)m—OR12 or —C(O)R13; wherein the alkyl, cycloalkyl, bicycloalkyl, heterocycloalkyl, aryl, or heteroaryl moieties may be independently substituted with one to three R14.

### Claim 7 (depends on 6)

The compound according to claim 6 wherein R11 is independently hydrogen, C1-6alkyl, fluoro, —CF3, —CHF2 or —OR12; and R12 is hydrogen, C1-6alkyl, —CF3 or C6-10aryl.

### Claim 8 (depends on 7)

The compound according to claim 7 wherein R3 is phenyl, naphthalene, 2,3-dihydro-1H-indene, quinoline, isoquinoline, pyrazole, benzo[b]furan, 2,3-dihydrobenzofuran, 1,2-benzisothiazole, 1,3-benzothiazole, benzofuro[3,2-c]pyridine, pyridine, carbazole, benzo[d]isoxazole, benzocyclobutane, 1,2,3,4-tetrahydronaphthalene, dibenzo[b,d]thiophene, dibenzo[b,d]furan or cinnoline.

### Claim 9 (depends on 8)

The compound according to claim 8 wherein R10 is hydrogen, chloro, fluoro, bromo, cyano, —CF3, —OCF3, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, cyclopropyl, cyclobutyl, bicycloalkyl, hydroxyl, methoxy, pyrazole, isothiazole, thiazole, 1,3,4-thiadiazole, isoxazole, oxazole, pyridine, piperidine, benzofuran, benzo[d][1,3]dioxole, tetrahydropyran or phenyl; wherein said C1-6alkyl, bicycloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl moieties may be optionally independently substituted with one to three R14.

### Claim 10 (depends on 9)

The compound according to claim 9 wherein R2a and R2b are hydrogen or C1-6alkyl; t is zero and m is zero; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 5)

The compound according to claim 5 wherein R3 is C6-10aryl or 5- to 14-membered heteroaryl;
R4a, R4b, R5a, R5b, R6, R7 and R8 are each independently hydrogen or C1-6alkyl;
R14 is independently hydrogen, C1-6alkyl, chloro, bromo or fluoro, —CF3, —CHF2 or —OR9;
and R17 is independently hydrogen or —CF3 or phenyl; wherein said phenyl moiety may be independently substituted with hydrogen or one to three halogen;
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The compound according to claim 11 wherein R3 is phenyl, naphthalene, 2,3-dihydro-1H-indene, quinoline, isoquinoline, pyrazole, benzo[b]furan, 2,3-dihydrobenzofuran, 1,2-benzisothiazole, 1,3-benzothiazole, benzofuro[3,2-c]pyridine, pyridine, carbazole, benzo[d]isoxazole, 1,2,3,4-tetrahydronaphthalene, dibenzo[b,d]thiophene, dibenzo[b,d]furan, benzoyclobutane or cinnoline;
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The compound according to claim 12 wherein R10 is hydrogen, chloro, fluoro, bromo, cyano, —CF3, —OCF3, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, cyclopropyl, cyclobutyl, bicycloalkyl, hydroxyl, methoxy, pyrazole, isothiazole, thiazole, 1,3,4-thiadizaole, isoxazole, oxazole, pyridine, piperidine, benzofuran, benzo[d][1,3]dioxole, tetrahydropyran or phenyl; wherein said alkyl, cycloalkyl, bicycloalkyl, heterocycloalkyl, heteroaryl or aryl moieties are optionally substituted with one to three hydrogen, fluoro or —CF3;
or a pharmaceutically acceptable salt thereof.

### Claim 14

A compound selected from the group consisting of:
7-(4-methyl-1H-imidazol-1-yl)-2-(2-{2-[2-(trifluoromethyl)-1,3-thiazol-4-yl]phenoxy}ethyl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
2-{(1S)-2-[4-fluoro-2-(trifluoromethyl)phenoxy]-1-methylethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
7-(4-methyl-1H-imidazol-1-yl)-2-(2-{2-[3-(trifluoromethyl)isoxazol-5-yl]phenoxy}ethyl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
2-(2-{[4-fluoro-2-(trifluoromethyl)-1,3-benzothiazol-7-yl]oxy}ethyl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
2-{2-[2-(3,3-difluorocyclobutyl)-4-fluorophenoxy]ethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
7-(4-methyl-1H-imidazol-1-yl)-2-(2-{[2-(trifluoromethyl)-1,3-benzothiazol-7-yl]oxy}ethyl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, trifluoroacetate salt;
7-(4-methyl-1H-imidazol-1-yl)-2-(2-{2-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]phenoxy}ethyl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
2-{2-[4-fluoro-2-(1,1,1-trifluoro-2-methylpropan-2-yl)phenoxy]ethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
2-{2-[2-(bicyclo[1.1.1]pent-1-yl)phenoxy]ethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
2-{(2S)-1-[4-chloro-2-(trifluoromethyl)phenoxy]propan-2-yl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
2-{2-[(2,2-difluoro-2,3-dihydro-1H-inden-4-yl)oxy]ethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
2-{2-[(2,2-difluoro-1,3-benzodioxol-4-yl)oxy]ethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione; and
2-{2-[2-(bicyclo[1.1.1]pent-1-yl)-4-chlorophenoxy]ethyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione.
or a pharmaceutically acceptable salt of any of the above.

### Claim 15

A method for treating a mammal having a disease or condition selected from the group consisting of neurological and psychiatric disorders comprising administering to the mammal a therapeutically effective amount of the compound of any of the preceding claims or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 14)

A method according to claim 14 wherein the disease or condition is Niemann Pick type C.

### Claim 17 (depends on 14)

A method according to claim 14 wherein the disease or condition is treating Alzheimer's disease.

### Claim 18

A pharmaceutical composition comprising a compound of any of the preceding claims or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle, diluent or carrier.

### Claim 19 (depends on 1)

A pharmaceutical combination comprising a therapeutically effective amount of a composition comprising:
a first compound, the first compound being a compound of the Formula I of claim 1 or a pharmaceutically acceptable salt thereof;
a second compound, the second compound being an atypical antipsychotic, a cholinesterase inhibitor, Dimebon, or NMDA receptor antagonist; and an optional pharmaceutical carrier, excipient or diluent.

### Claim 20

The compound of Formula II
and tautomers or salt forms thereof.
